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Evanthia Bernitsas, MD,1 Wei Wei, PhD,2
and Daniel D. Mikol, MD, PhD1
Objective: To explore the potential of dexrazoxane to
suppress subclinical cardiotoxicity in MS patients receiv-
ing mitoxantrone. Methods: An open-label study was per-
formed to evaluate possible subclinical cardiotoxicity in
multiple sclerosis patients treated quarterly with mitox-
antrone (48mg/m2 cumulative), with and without con-
comitant dexrazoxane, using blinded serial radionucleide
ventriculography. Results: No patient experienced symp-
toms of heart failure. Patients receiving dexrazoxane,
which is cardioprotective for anthracyclines, exhibited a
significantly lesser decline in left ventricular ejection
fraction (mean change, 3.80% vs 8.55%, p < 0.001).
Interpretation: These results support a cardioprotective
effect of dexrazoxane in mitoxantrone treated multiple
sclerosis patients.
Ann Neurol 2006;59:206–209
Dose-dependent cardiomyopathies can result from an-
thracyclines and structurally related anthracenediones
such as mitoxantrone (MX), although cardiotoxic risk
is greater for anthracyclines.1 For doxorubicin, the
risk of congestive heart failure (CHF) is 3% at a
threshold of 400mg/m2, 7% at 550mg/m2, and 18%
at 700mg/m2.2 In view of an approximate potency
ratio of 1 to 5,3 700mg/m2 of doxorubicin corre-
sponds to approximately140mg/m2 of MX (the recom-
mended limit in MS); oncological studies suggest that
the risk of CHF at this threshold is approximately
2.6%.4
Subclinical decline in cardiac function likely occurs
more frequently than CHF.1,5 Of 1,378 MS patients
receiving a mean of 60.5mg/m2 MX, two cases of CHF
were seen, but of the 779 patients who underwent se-
rial measurements, 17 (2.18%) had an asymptomatic
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decrease in left ventricular ejection fraction (LVEF) be-
low 50%.6 The number of patients whose LVEF de-
creased by 10% or more was not reported in this cohort,
but an absolute decrease by greater than or equal to 10%
is grounds for withholding further treatment.4,7
Dexrazoxane (DRZ) is an iron-chelating cardiopro-
tective agent approved for use with doxorubicin.2 DRZ
has not been carefully tested in humans receiving MX,
but in animals it does protect against MX-associated
cardiotoxicity.8 Here, we examine pretreatment and
posttreatment LVEF and, as an exploratory outcome,
postinfusion cardiac troponin (cTn)-I, in 47 MS pa-
tients treated with four quarterly MX infusions with
and without DRZ.
Materials and Methods
The primary aims of this study were to assess change in
LVEF after 48mg/m2 MX and a possible cardioprotective ef-
fect of DRZ. There were no clinical or MRI end points in
this open-label study. All patients (n  47) initiating quar-
terly MX infusions at the University of Michigan MS Center
between July 2000 and May 2003 received at least four quar-
terly infusions and are included in this analysis. Importantly,
the multiple gated acquisition scan (MUGA) interpreter was
blinded regarding DRZ administration. Prior treatment with
anthracyclines or anthracenediones, pregnancy, or history of
cardiac disease precluded MX treatment. Because of variable
cumulative dose administered, no data were analyzed beyond
48mg/m2. Patients in the “DRZ” group were drawn from
a previously reported safety (including LVEF assessment) and
tolerability study of MX plus DRZ9; the majority of patients
in the DRZ group were enrolled after the safety study,
although there was overlap of several patients. Baseline de-
mographics among DRZ and DRZ groups were com-
pared regarding age and baseline LVEF (two sample t tests)
and sex (Fisher’s exact test). All data were examined for out-
liers and normality using scatterplots, histograms, and nor-
mal probability plots. This study was approved by the Uni-
versity of Michigan Institutional Review Board.
All patients received intravenous MX (12mg/m2) over 15
to 30 minutes. In individuals receiving DRZ (600mg/m2), it
was administered intravenously 30 minutes before MX. The
ratio of DRZ to MX (50:1) was chosen because in oncology
DRZ generally has been used in a 10 to 1 combination with
doxorubicin. Given the approximately 1 to 5 potency ratio
for doxorubicin to MX, this corresponds to a 50 to 1 DRZ
to MX ratio.
In addition to routine preinfusion laboratory monitoring,
cardiac troponin (cTn)-I was checked within 7 days of infu-
sion and repeated 24 to 72 hours and 8 to 12 days after
treatment, based on reports that both acute and delayed cTn
increases can occur after anthracycline treatment.10 MUGA
scans performed at baseline and at end of study, 2 to 3
months after the fourth infusion, were analyzed by the same
evaluator, who was completely blinded, having no knowledge
of dexrazoxane coadministration. Mean (paired t test) and
median (Wilcoxon signed ranks test) change in LVEF for
each group were compared, whereas the mean change in
LVEF between groups was compared using the two sample t
test. Between group comparison of the number of subjects
with absolute LVEF change greater than or equal to 10%
was assessed using the Fisher’s exact test. A linear regression
model was also considered to assess the effect of DRZ, ad-
justed for baseline factors.
Results
Overall, 47 patients were enrolled (28 DRZ, 19
DRZ), including 30 females (63.8%; 66.7% DRZ,
33.3% DRZ) and 17 males (36.2%; 47.1% DRZ,
52.9% DRZ). Mean and median ages were 45.6 and
48, respectively (45 and 47.5 for the DRZ group;
46.5 and 49 for the DRZ group). Neither outliers
nor departure of the data for continuous variables from
normal distribution were detected in our data set.
There are no significant differences between the
DRZ and DRZ groups regarding age (p  0.6),
sex (p  0.22), or baseline LVEF (p  0.18), and
none of the baseline factors has a statistically significant
impact on the cardioprotective effect of DRZ. None of
our patients experienced CHF or other clinical signs of
cardiac dysfunction at any time during the study.
As shown in Tables 1 and 2, the mean absolute
LVEF change for all 47 subjects was 5.72%, a sig-
nificant decrease from baseline (p  0.001; 95% con-
fidence interval, 4.62 to 6.83). Mean LVEF change
was 8.55% for the DRZ group (p  0.001; 95%
confidence interval, 6.88% to 10.23%) and
3.80% for the DRZ group (p  0.001; 95% con-
fidence interval 2.80% to 4.80%), indicating a car-
dioprotective effect for DRZ (p  0.001). Perhaps
more striking, LVEF decreased by greater than or equal
to 10% in 7 of 19 (37%) DRZ subjects, compared
with 0 of 28 in the DRZ group (p  0.001). As an
exploratory measure, we assessed the potential utility of
cTn-I as an early marker of susceptibility to MX-
associated cardiac injury. None of the patients’ cTn-I
values obtained at two time points after each of four
infusions, as specified in Materials and Methods, ex-
ceeded the upper limit of normal, 0.39ng/ml (data not
shown).
Discussion
Our results reinforce that subclinical cardiac toxicity
secondary to MX may be much more common than
symptomatic cardiac injury, which has also been ob-
served in small case series.11 Although MUGA assess-
ment of LVEF may have intrinsic variability, it is an
objective and blinded outcome, and the decreases in
LVEF observed are not simply a result of measurement
variability, given that LVEF did not increase in any of
the 47 individuals. A smaller change in LVEF
(3.80%) was seen in the DRZ versus the DRZ
group (8.55%; p  0.001), and LVEF decreased by
greater than or equal to 10% in 0 of 28 DRZ pa-
tients, compared with 7 of 19 DRZ patients (p 
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0.001), demonstrating a cardioprotective effect, which
has also been observed experimentally.8 Although this
was not a randomized study, MUGA assessment was
blinded regarding DRZ, and no patient receiving the
four infusion regimen at our MS Center during the
study period was excluded. This work does not address
whether DRZ affects the therapeutic benefit of MX.
However, it is reassuring that DRZ does not compro-
mise the antileukemic efficacy of doxorubicin.12 Fur-
thermore, both DRZ and MX have separately been
Table 2. Change in LVEF (MUGA) for DRZ and DRZ subjects—Group Results









Mean (%) 66.5 62.7 0.001 69.5 61.0 0.001
SD (%) 6.4 6.6 8.1 7.6
95% Confidence interval (%) 64.0–69.0 60.1–65.3 65.6–73.4 57.3–64.6
Median (%) 66.5 63.0 0.001 71.0 62.0 0.001
Range (%) 56–79 50–72 51–83 44–77
Mean change in LVEF (%) 3.8 8.6 0.001
Group pre- and post-MX LVEF outcomes are shown. Mean LVEF decreased for DRZ and DRZ groups (p  0.001). The mean change
in LVEF was significantly less for the DRZ group (3.8% compared with 8.6%; p  0.001).
LVEF  left ventricular ejection fraction; DRZ  dexrazoxane.










ChangePre Post Pre Post
1 71% 64%  7% 1 72% 64%  8%
2 62% 56%  6% 2 71% 65%  6%
3 67% 62.5%  4.5% 3 66% 58%  8%
4 74% 71%  3% 4 66% 57%  9%
5 57% 50%  7% 5 83% 71%  12%
6 79% 71%  8% 6 60% 51%  9%
7 66% 64%  2% 7 75% 62%  13%
8 77% 71%  6% 8 67% 57.5%  9.5%
9 57% 54%  3% 9 75% 61%  14%
10 65% 56%  9% 10 58% 58% 0%
11 77% 70%  7% 11 83% 72%  11%
12 68% 65%  3% 12 73% 63%  10%
13 62% 62% 0% 13 51% 44%  7%
14 58% 50%  8% 14 73% 63%  10%
15 62% 58%  4% 15 64% 54%  10%
16 64% 63%  1% 16 78% 77%  1%
17 56% 53%  3% 17 71% 62%  9%
18 63% 62%  1% 18 70% 63%  7%
19 67% 64%  3% 19 65% 56%  9%
20 69% 63%  6%
21 70% 68%  2%
22 72% 71%  1%
23 70% 68%  2%
24 63% 60%  3%
25 61% 59%  2%
26 72% 72% 0%
27 73% 70%  3%
28 60% 58%  2%
Individual LVEF results (MUGA) before and after treatment with quarterly MX infusions (12mg/m2 each, 48mg/m2 cumulative) are shown for
subjects in DRZ and DRZ groups. The eight subjects (all in DRZ group) whose LVEF decreased by greater than or equal to 10% are
indicated in bold italics.
LVEF  left ventricular ejection fraction; DRZ  dexrazoxane.
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shown to ameliorate disease in experimental allergic en-
cephalomyelitis, and together DRZ  MX is more ef-
ficacious than either agent alone.13
The occurrence and severity of MX cardiotoxicity is
unpredictable. Preexisting cardiac disease seems a logi-
cal risk factor,14 but there remains a need for an early
marker of myocardial injury that can predict subse-
quent impairment in ventricular function. cTn iso-
forms are sensitive markers of ischemic myocardial
damage, and animal studies demonstrate that the
pathological severity of doxorubicin or MX-induced
cardiomyopathy correlates with serum cTn levels, al-
though cTn may not increase until after several infu-
sions.8 Here, we show that post-MX cTn-I is not an
effective predictor of cardiac injury through 48mg/m2
MX. Further studies are needed to investigate the pos-
sible utility of cTn-I or cTn-T as biomarkers for sub-
clinical cardiotoxicity beyond 48mg/m2. In the mean-
time, frequent cardiac monitoring seems prudent. Note
that product labeling for MX was updated in March
2005, in view of postmarketing surveillance showing
that cardiac function may diminish early in the treat-
ment course, such that cardiac monitoring is now rec-
ommended before each MX infusion.15
Despite the potential for cardiac and other toxicities
associated with MX, its potential benefit may outweigh
these risks in the individual patient. If cardiac risk
could be mitigated, such as with DRZ, the risk to ben-
efit ratio could be improved, and this might enable the
current dose limit of MX to be surpassed in at least
some individuals benefiting from therapy. A larger ran-
domized, prospective clinical trial of MX with and
without DRZ seems warranted before considering
DRZ for general use.
This work was supported by a grant from Immunex Corp
(D.D.M.).
We thank K. L. Bennett RN, MSCN for her excellence in patient
care and assistance with this study.
References
1. Pai VB, Nahata MC. Cardiotoxicity of chemotherapeutic
agents: incidence, treatment and prevention. Drug Saf 2000;22:
263–302.
2. Swain SM. Adult multicenter trials using dexrazoxane to pro-
tect against cardiac toxicity. Semin Oncol 1998;25:43–47.
3. Sparano BM, Gordon G, Hall C, et al. Safety assessment of
new anticancer compound, mitoxantrone, in beagle dogs: com-
parison with doxorubicin. II. Histologic and ultrastructural pa-
thology. Cancer Treat Rep 1982;66:1145–1158.
4. Cohen BA, Mikol DD. Mitoxantrone treatment of multiple
sclerosis: safety considerations. Neurology 2004;63:S28–S32.
5. Unverferth DV, Unverferth BJ, Balcerzak SP, et al. Cardiac eval-
uation of mitoxantrone. Cancer Treat Rep 1983;67:343–350.
6. Ghalie RG, Edan G, Laurent M, et al. Cardiac adverse effects
associated with mitoxantrone (Novantrone) therapy in patients
with MS. Neurology 2002;59:909–913.
7. Gonsette RE. Mitoxantrone in progressive multiple sclerosis:
when and how to treat? J Neurol Sci 2003;206:203–208.
8. Herman EH, Zhang J, Rifai N, et al. The use of serum levels of
cardiac troponin T to compare the protective activity of dexra-
zoxane against doxorubicin- and mitoxantrone-induced cardio-
toxicity. Cancer Chemother Pharmacol 2001;48:297–304.
9. Mikol DD, LaHoud, O, Bernitsas E. Safety of mitoxantrone
plus dexrazoxane in multiple sclerosis patients. Neurology 2003;
60:A478.
10. Fleming SM, Daly KM. Cardiac troponins in suspected acute
coronary syndrome: a meta-analysis of published trials. Cardi-
ology 2001;95:66–73.
11. Avasarala JR, Cross AH, Clifford DB, et al. Rapid onset
mitoxantrone-induced cardiotoxicity in secondary progressive
multiple sclerosis. Mult Scler 2003;9:59–62.
12. Lipshultz SE, Rifai N, Dalton VM, et al. The effect of dexra-
zoxane on myocardial injury in doxorubicin-treated children
with acute lymphoblastic leukemia. N Engl J Med 2004;351:
145–153.
13. Weilbach FX, Chan A, Toyka KV, Gold R. The cardioprotec-
tor dexrazoxane augments therapeutic efficacy of mitoxantrone
in experimental autoimmune encephalomyelitis. Clin Exp Im-
munol 2004;135:49–55.
14. Von Hoff DD, Layard MW, Basa P, et al. Risk factors for
doxorubicin-induced congestive heart failure. Ann Intern Med
1979;91:710–717.
15. OSI Pharmaceuticals http://www.osip.com/osi. accessed Oct
15, 2005.
Bernitsas et al: Dexrazoxane and Mitoxantrone 209
